Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Warning Letters Reinforce FDA Ban On Supplement/Drug Combinations

This article was originally published in The Tan Sheet

Executive Summary

FDA warns Bayer HealthCare that its two products combining aspirin with dietary supplement ingredients are unapproved new drugs

You may also be interested in...



US FDA Suggests Adding Antioxidants To Drug Formulations To Mitigate Nitrosamine Risks

Agency recommends “mitigation strategies” also including designing formulations that incorporate excipients such as sodium carbonate which modify the micro-environment to neutral or basic pH.

P&G Wraps Launch Of Super C Supplement Brand In Co-Packaging With DayQuil And NyQuil OTCs

P&G could be using a door left open in FDA’s 2015 proposed rule that questioned the safety of offering co-packaged supplements and drugs. With OTC drug and supplement firms always looking to drive sales growth, competitors large and small could follow P&G through the door.

OTC, Supplement Co-Packaging Potential Could Be Clipped By FDA Proposed Rule

Innovus Pharmaceuticals is among the firms offering supplements and OTC drugs sold together, an option CRN trade group encourages FDA to allow. FDA will determine on a case-by-case basis whether already available co-packaged OTCs and supplements violate a proposed rule on drug co-packaging.

Related Content

Topics

UsernamePublicRestriction

Register

PS102252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel